Evotec AG : Estimates raised on brighter 2018 outlook for adj. EBITDA
>2018 estimates raised after upgrade to 2018 outlook - Evotec has increased its profitability guidance for 2018 and now expects a > 45% increase to its adjusted group EBITDA (previous est. around +30%) in 2018 vs last year (2017: € 58.4m). This increase primarily reflects Evotec’s strong business performance, which has boosted the margin contribution, and important scientific milestone achieved in the Q4 2018 as well as an increase in other operating income due to fac...Evotec is a holding company engaged as a drug discovery solutions company providing drug discovery capabilities to pharmaceutical and biotechnology companies as well as to academic institutions. These drug discovery solutions are provided in form of fee-for service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Co. is primarily involved in the areas of neuroscience, pain, metabolic diseases, oncology and inflammation. Co. provides its drug discovery activities under the banners of EVT Execute, EVT Integrate and EVT Innovate. Co.'s operations are divided into two segments: EVT Execute and EVT Innovate.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.